Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Improving combination drug trials using ‘definitive screening designs’

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Strohbehn, G. W., Kacew, A. J., Goldstein, D. A., Feldman, R. C. & Ratain, M. J. Nat. Biotechnol. 39, 1504–1510 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Pharmacy Benefits, V. A. Management Services. Ledipasvir/Sofosbuvir (Harvoni®) National Drug Monograph (2014).

  3. Shlay, J. C. et al. Terry Beirn Community Programs for Clinical Research on AIDS. J. Am. Med. Assoc. 280, 1590–1595 (1998).

    Article  CAS  Google Scholar 

  4. Bosch, J. et al. BMJ 324, 699–702 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wilcox, M. H. et al. N. Engl. J. Med. 376, 305–317 (2017).

    Article  CAS  PubMed  Google Scholar 

  6. Mulangu, S. et al. N. Engl. J. Med. 381, 2293–2303 (2019).

    Article  CAS  PubMed  Google Scholar 

  7. Muthas, D., Boyer, S. & Hasselgren, C. MedChemComm 4, 1058–1065 (2013).

    Article  CAS  Google Scholar 

  8. Maddipatla, M. U.S. signs $450 million contract with Regeneron for COVID-19 therapy. Reuters (2020).

  9. Abinader, L. G. U. S. Government funding of Lilly’s LY-CoV555 antibody against COVID-19. Knowledge Ecology International (2020); https://www.keionline.org/34308

  10. Anonymous. Regeneron enters agreement with BARDA on antibody therapy for Ebola. GEN Biotechnol. https://www.genengnews.com/topics/drug-discovery/regeneron-enters-agreement-with-barda-on-antibody-therapy-for-ebola/ (2015).

  11. Box, G. E. P. Improving Almost Anything: Ideas and Essays rev. edn (Wiley-Interscience, 2006).

  12. Fisher, R. A. The Design of Experiments (Oliver and Boyd, 1937).

  13. CDER & CBER. ICH guidance Q8(R2) Pharmaceutical Development. (2020).

  14. CDER & CBER. ICH Guidance Document Q9 Quality Risk Management. (2006).

  15. CDER & CBER. ICH Guidance Document Q10 Pharmaceutical Quality System. (2009).

  16. Palmer, A. C., Izar, B., Hwangbo, H. & Sorger, P. K. Clin. Cancer Res. 28, 368–377 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Jones, B. & Nachtsheim, C. J. J. Qual. Technol. 43, 1–15 (2011).

    Article  Google Scholar 

  18. Jones, B. & Nachtsheim, C. J. J. Qual. Technol. 45, 121–129 (2013).

    Article  Google Scholar 

  19. Fisher, R. A. J. Ministry Agric. 33, 503–515 (1926).

    Google Scholar 

  20. Chakraborty, B., Collins, L. M., Strecher, V. J. & Murphy, S. A. Stat. Med. 28, 2687–2708 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jaynes, J., Ding, X., Xu, H., Wong, W. K. & Ho, C.-M. Stat. Med. 32, 307–318 (2013).

    Article  PubMed  Google Scholar 

  22. Huang, H. & Chen, X. Comput. Stat. Data Anal. 157, 107150 (2021).

    Article  Google Scholar 

  23. Xiao, Q., Wang, L. & Xu, H. Stat. Med. 38, 236–246 (2019).

    Article  PubMed  Google Scholar 

  24. Abhyankar, M. M. et al. Front. Immunol. 12, 683157 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zhao, H. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.12.21.473715 (2022).

  26. Taylor, P. R. et al. Linxian Nutrition Intervention Trials Study Group. Cancer Res. 54(suppl), 2029s–2031s (1994).

    CAS  PubMed  Google Scholar 

  27. Yu, L. X. et al. AAPS J. 16, 771–783 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Nat. Rev. Drug Discov. 11, 191–200 (2012).

    Article  CAS  PubMed  Google Scholar 

  29. Paul, S. M. et al. Nat. Rev. Drug Discov. 9, 203–214 (2010).

    Article  CAS  PubMed  Google Scholar 

  30. Pharma Intelligence. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021); https://pharmaintelligence.informa.com/resources/product-content/2021-clinical-development-success-rates

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Dodds.

Ethics declarations

Competing interests

The authors are employees of Lumen Bioscience.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dodds, M., Roberts, J. & Finrow, B. Improving combination drug trials using ‘definitive screening designs’. Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01521-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-022-01521-w

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing